$ETST Dr. Michel Aube, ETST’s CEO & Chief Science Officer, adds, “I am very impressed with the formula that came from Gabriel’s idea, and look forward to seeing the results of our new study. We are currently in the process of finalizing our current CBD patents and look forward to launching in 2018. The new CBD formula currently being studied by our advisory board will keep us innovative and continue to allow us to offer specialized natural CBD based remedies. Moreover, we will push this idea further by creating an improved generic pharmaceutical drug.”